文献速递中药与中成药合理使用中医内科

芍药甘草附子汤与托法替布经CYP450酶的草药-药物相互作用

Herb-drug interaction between Shaoyao-Gancao-Fuzi decoction and tofacitinib via CYP450 enzymes.
PubMed 文献 · J Ethnopharmacol · 2022-06-03

本研究探讨芍药甘草附子汤(SGFD)对CYP450酶活性的影响及其与托法替布的潜在草药-药物相互作用。采用cocktail法评估SGFD对大鼠CYP1A2、3A4、2A6、2E1和2C9活性的影响,并研究SGFD处理两周后托法替布的药代动力学。结果显示SGFD显著抑制CYP3A4活性,增加托法替布的Cmax和AUC0-∞,机制涉及降低CYP3A基因转录及主要成分与CYP3A4活性位点结合。

要点

  • SGFD显著抑制CYP3A4活性,对CYP1A2有激活作用,对CYP2E1和2C9无影响。
  • SGFD处理14天后托法替布的Cmax和AUC0-∞明显增加。
  • 机制为SGFD降低CYP3A基因转录,且甘草次酸等成分占据CYP3A4活性位点。

核心结论

  • SGFD增加托法替布的系统暴露,影响关键代谢酶CYP3A的活性和基因表达。
  • 这些发现有助于预测SGFD的草药-药物相互作用以保障临床安全用药。

研究设计与样本

  • 采用cocktail法评估SGFD对CYP1A2、3A4、2A6、2E1和2C9活性的影响。
  • 研究大鼠口服托法替布在SGFD处理两周后的药代动力学。
  • 采用RT-qPCR和分子对接揭示草药-药物相互作用的机制。

主要发现

  • SGFD对CYP2E1和2C9活性无影响,对CYP2A6有弱影响,对CYP1A2有激活作用。
  • SGFD对CYP3A4活性有显著抑制作用。
  • SGFD处理14天后托法替布的Cmax和AUC0-∞明显增加。
  • SGFD显著降低CYP3A基因转录。
  • 分子对接证实甘草次酸、甘草酸和甘草苷通过占据CYP3A4活性位点并与关键残基有利相互作用产生抑制活性。

临床怎么用

  • 临床使用SGFD联合托法替布时需关注CYP3A4抑制导致的托法替布暴露增加,注意监测。
  • SGFD对CYP1A2有激活作用,可能影响经CYP1A2代谢药物的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGY RELEVANCE: Shaoyao-Gancao-Fuzi decoction (SGFD), a well-known traditional Chinese medicine formula, was originally described in "Treatise on Febrile Diseases" and has been extensively used to dispel wind, eliminate dampness and treat paralysis. It is widely used for the treatment of rheumatoid arthritis in clinic. However, the effect of SGFD on the activity of cytochrome P450 enzymes (CYP450s) and the herb-drug interactions are rarely studied. OBJECTIVE: The aim of this study was to investigate the effect of SGFD on the activity of CYP450s and evaluate the potential herb-drug interactions between SGFD and tofacitinib, commonly used disease-modifying antirheumatic drug in rheumatoid arthritis. MATERIALS AND METHODS: The cocktail approach was employed to assess the effect of SGFD on the activity of CYP1A2, 3A4, 2A6, 2E1, and 2C9. The pharmacokinetic profile of oral administration of tofacitinib in rats after two weeks of treatment with SGFD was investigated. RT-qPCR and molecular docking were performed to unveil the underlying mechanism of the herb-drug interaction. RESULTS: SGFD had no effect on the activities of CYP2E1 and 2C9, had a weak effect on CYP2A6, and had activatory effect on CYP1A2. However, it had a dramatically inhibitory effect on the activity of CYP3A4. Simultaneously, the values of Cmax and AUC0-∞ of tofacitinib were obviously increased after treatment with SGFD for 14 days. The mechanism study manifested that SGFD significantly reduced the gene transcription of CYP3A. Molecular docking work confirmed that the inhibitory activity of glycyrrhetinic acid, glycyrrhizic acid and liquiritin, the main ingredients of SGFD, occurred by occupying the active sites of CYP3A4 and by making favorable interactions with its key residues. CONCLUSIONS: The system exposure of tofacitinib was increased by SGFD. SGFD could affect the activity and gene expression of the key metabolic enzyme CYP3A. These findings give a clear understanding to predict herb-drug interaction of SGFD for safe clinical use in future.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Lin L, Wang Y, Shao S, et al. Herb-drug interaction between Shaoyao-Gancao-Fuzi decoction and tofacitinib via CYP450 enzymes. J Ethnopharmacol. 2022. PMID: 35667582. doi:10.1016/j.jep.2022.115437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。